NERVGEN PHARMA CORP News

NervGen Pharma GAAP EPS of -$0.38

Seeking AlphaApr 17 11:54 ET

NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update

NervGen Pharma Corp. (NGEN.V), a biotech company developing solutions to treat nervous system damage, reported a net loss of $22.4 million, or $(0.38) per basic and diluted share for the year ended De

MT NewswiresApr 17 10:45 ET

NervGen Pharma GAAP EPS of -$0.07

Seeking AlphaNov 9, 2023 12:04 ET

NervGen Pharma GAAP EPS of -$0.08

Seeking AlphaMay 15, 2023 12:27 ET

NervGen Pharma Appoints Michael Kelly as President & CEO

Seeking AlphaApr 10, 2023 09:23 ET

NervGen Pharma GAAP EPS of -$0.39

Seeking AlphaMar 30, 2023 09:39 ET

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 42% Below Their Intrinsic Value Estimate

Yahoo FinanceJan 6, 2023 06:02 ET

NervGen Grants 400K Stock Options to Directors

Seeking AlphaNov 16, 2022 05:30 ET

NervGen Pharma Reports Q3 Results

Seeking AlphaNov 14, 2022 10:01 ET

NervGen Pharma Awarded up to $1.5M US Department of Defense Funding

NervGen Pharma (OTCQX:NGENF) has been awarded up to $1.5M in US Department of Defense funding from the Military Operational Medicine Research Program to evaluate NervGen's NVG-291-R as a therapeutic t

Seeking AlphaOct 12, 2022 09:04 ET

NervGen Pharma Appoints Bill Radvak as Interim CEO

NervGen Pharma (OTCQX:NGENF) notifies that the board and Paul Brennan have mutually agreed that Mr. Brennan will step down as President & CEO and a member of the board, effective immediately. The

Seeking AlphaSep 23, 2022 03:39 ET

NervGen Pharma GAAP EPS of -$0.13

NervGen Pharma press release (OTCQX:NGENF): Q2 GAAP EPS of -$0.13. Cash position enhanced by over $22M.

Seeking AlphaAug 10, 2022 17:42 ET

NervGen Pharma GAAP EPS of -$0.11

NervGen Pharma press release (OTCQX:NGENF): Q1 GAAP EPS of -$0.11.NervGen had cash and investments of $12.8 million as of March 31, 2022, compared to $5.0 million as of March 31, 2021. The net cash

Seeking AlphaMay 12, 2022 09:05 ET

NervGen Pharma gets safety panel nod to advance in phase 1 trial of NVG-291

NervGen Pharma (OTCQX:NGENF) received approval from A safety review committee to advance to the second cohort in the multiple ascending dose (MAD) portion of its phase 1 trial of NVG-291. The company

Seeking AlphaMar 15, 2022 15:46 ET

NervGen Pharma Closes $9.2 Million Bought Deal Financing

10:46 AM EST, 11/12/2021 (MT Newswires) -- NervGen Pharma Corp. (NGEN.V), a clinical-stage biotech company, said Friday that it has completed a $9.2 million bought deal financing. This included the f

MT NewswiresNov 12, 2021 12:01 ET

NervGen Pharma Upsizes Bought Deal Financing; Falls 11.1%

01:51 PM EDT, 11/05/2021 (MT Newswires) -- NervGen Pharma Corp., (NGEN.V), a clinical-stage biotech company, said Friday that it has increased the size of its $5 million bought deal offering. Under t

MT NewswiresNov 6, 2021 20:14 ET

Industrial Alliance Initiates Coverage On NervGen Pharma with Speculative Buy Rating, Announces Price Target of $6

Industrial Alliance initiates coverage on NervGen Pharma (OTC:NGENF) with a Speculative Buy rating and announces Price Target of $6.

Benzinga Real-time NewsJul 13, 2021 08:55 ET

NervGen Pharma analyst ratings

DateResearch FirmActionCurrentPT 7/13/21Industrial AllianceInitiates Coverage OnSpeculative Buy6.0

Benzinga Analyst RatingsJul 13, 2021 08:53 ET